Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EBIT (2020 - 2025)

Historic EBIT for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$80.4 million.

  • Relay Therapeutics' EBIT rose 1658.0% to -$80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.1 million, marking a year-over-year increase of 1385.33%. This contributed to the annual value of -$372.5 million for FY2024, which is 14.26% up from last year.
  • As of Q3 2025, Relay Therapeutics' EBIT stood at -$80.4 million, which was up 1658.0% from -$76.8 million recorded in Q2 2025.
  • Relay Therapeutics' EBIT's 5-year high stood at -$42.4 million during Q1 2021, with a 5-year trough of -$193.6 million in Q2 2021.
  • For the 5-year period, Relay Therapeutics' EBIT averaged around -$86.9 million, with its median value being -$84.9 million (2025).
  • In the last 5 years, Relay Therapeutics' EBIT crashed by 59836.57% in 2021 and then skyrocketed by 5980.42% in 2022.
  • Over the past 5 years, Relay Therapeutics' EBIT (Quarter) stood at -$67.7 million in 2021, then dropped by 7.57% to -$72.9 million in 2022, then fell by 26.55% to -$92.2 million in 2023, then grew by 7.83% to -$85.0 million in 2024, then increased by 5.4% to -$80.4 million in 2025.
  • Its EBIT stands at -$80.4 million for Q3 2025, versus -$76.8 million for Q2 2025 and -$84.9 million for Q1 2025.